What is molecular and cellular imaging?

Molecular and Cellular MR Imaging

Volumn , Issue , 2007, Pages 1-9

  Modo, Michel M J ^a   Bulte, Jeff W M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85043273964     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (57)

1. Gawad, C., Towards molecular medicine: a case for a biological periodic table, Am. J. Pharmacogenomics, 5, 207–211, 2005.
2. Dietel, M. and Sers, C., Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review, Virchows Arch., 448(6), 744–755, 2006.
3. Steel, M., Molecular medicine: promises, promises? J. R. Soc. Med., 98, 197–199, 2005.
4. Bailey, W.J. and Ulrich, R., Molecular profiling approaches for identifying novel biomarkers, Expert Opin. Drug Saf., 3, 137–151, 2004.
5. Heckl, S., Pipkorn, R., Nagele, T., Vogel, U., Kuker, W., and Voight, K., Molecular imaging: bridging the gap between neuroradiology and neurohistology, Histol. Histopathol., 19, 651–668, 2004.
6. Rudin, M. and Weissleder, R., Molecular imaging in drug discovery and development, Nat. Rev. Drug Discov., 2, 123–131, 2003.
7. Weissleder, R., Molecular imaging: exploring the next frontier, Radiology, 212, 609–614, 1999.
8. Calvo, B.F. and Semelka, R.C., Beyond anatomy: MR imaging as a molecular diagnostic tool, Surg. Oncol. Clin. N. Am., 8, 171–183, 1999.
9. Schwaiger, M. and Weber, W., Molecular imaging: dream or reality? Ernst Schering Res. Found. Workshop, 48, 1–18, 2004.
10. Herschman, H.R., Molecular imaging: looking at problems, seeing solutions, Science, 302, 605–608, 2003.
11. Piwnica-Worms, D., Schuster, D.P., and Garbow, J.R., Molecular imaging of host-pathogen interactions in intact small animals, Cell. Microbiol., 6, 319–331, 2004.
12. Gheysens, O. and Gambhir, S.S., Studying molecular and cellular processes in the intact organism, Prog. Drug Res., 62, 117–150, 2005.
13. Massoud, T.F. and Gambhir, S.S., Molecular imaging in living subjects: seeing fundamental biological processes in a new light, Genes Dev., 17, 545–580, 2003.
14. Staddon, S., Arranz, M.J., Mancama, D., Mata, I., and Kerwin, R.W., Clinical applications of pharmacogenetics in psychiatry, Psychopharmacology (Berl.), 162, 18–23, 2002.
15. Jasanoff, A., Functional MRI using molecular imaging agents, Trends Neurosci., 28, 120–126, 2005.
16. Ryan, J.M., Loy, R., and Tariot, P.N., Impact of molecular medicine on neuropsychiatry: the clinician’s perspective, Curr. Psychiatry Rep., 3, 355–360, 2001.
17. Jager, P.L., de Korte, M.A., Lub-de Hooge, M.N., van Waarde, A., Koopmans, K.P., Perik, P.J., and de Vries, E.G., Molecular imaging: what can be used today, Cancer Imaging, 5, S27–S32, 2005.
18. Pomper, M.G., Translational molecular imaging for cancer, Cancer Imaging, 5, S16–S26, 2005.
19. Levin, C.S., Primer on molecular imaging technology, Eur. J. Nucl. Med. Mol. Imaging, 32 (Suppl 2), S325–S345, 2005.
20. Frost, J.J., Molecular imaging of the brain: a historical perspective, Neuroimaging Clin. N. Am., 13, 653–658, 2003.
21. Hoh, C.K., Schiepers, C., Seltzer, M.A., Gambhir, S.S., Silverman, D.H., Czernin, J., Maddahi, J., and Phelps, M.E., PET in oncology: will it replace the other modalities? Semin. Nucl. Med., 27, 94–106, 1997.
22. Conti, P.S., Introduction to imaging brain tumor metabolism with positron emission tomography (PET), Cancer Invest., 13, 244–259, 1995.
23. Gibson, R.E., Burns, H.D., Hamill, T.G., Eng, W.S., Francis, B.E., and Ryan, C., Non-invasive radiotracer imaging as a tool for drug development, Curr. Pharm. Design, 6, 973–989, 2000.
24. Halldin, C., Gulyas, B., Langer, O., and Farde, L., Brain radioligands: state of the art and new trends, Q. J. Nucl. Med., 45, 139–152, 2001.
25. Kegeles, L.S. and Mann, J.J., In vivo imaging of neurotransmitter systems using radiolabeled receptor ligands, Neuropsychopharmacology, 17, 293–307, 1997.
26. Phelps, M.E., PET: the merging of biology and imaging into molecular imaging, J. Nucl. Med., 41, 661–681, 2000.
27. Czernin, J. and Phelps, M.E., Positron emission tomography scanning: current and future applications, Annu. Rev. Med., 53, 89–112, 2002.
28. Sasaki, M., Inoue, T., Tohyama, K., Oikawa, H., Ehara, S., and Ogawa, A., High-field MRI of the central nervous system: current approaches to clinical and microscopic imaging, Magn. Reson. Med. Sci., 2, 133–139, 2003.
29. Kwock, L., Localized MR spectroscopy: basic principles, Neuroimaging Clin. N. Am., 8, 713–731, 1998.
30. Guccione, S., Li, K.C., and Bednarski, M.D., Molecular imaging and therapy directed at the neovasculature in pathologies. How imaging can be incorporated into vascular-targeted delivery systems to generate active therapeutic agents, IEEE Eng. Med. Biol. Mag., 23, 50–56, 2004.
31. Artemov, D., Molecular magnetic resonance imaging with targeted contrast agents, J. Cell. Biochem., 90, 518–524, 2003.
32. Lorusso, V., Pascolo, L., Fernetti, C., Anelli, P.L., Uggeri, F., and Tiribelli, C., Magnetic resonance contrast agents: from the bench to the patient, Curr. Pharm. Design, 11, 4079–4098, 2005.
33. Podulso, J.F., Wengenack, T.M., Curran, G.L., Wisniewski, T., Sigurdsson, E.M., Macura, S.I., Borowski, B.J., and Jack, C.R., Molecular targeting of Alzheimer’s amyloid plaques for contrastenhanced magnetic resonance imaging, Neurobiol. Dis., 11, 315–329, 2002.
34. Modo, M., Hoehn, M., and Bulte, J.W., Cellular MR imaging, Mol. Imaging, 4, 143–164, 2005.
35. Delikatny, E.J. and Poptani, H., MR techniques for in vivo molecular and cellular imaging, Radiol. Clin. N. Am., 43, 205–220, 2005.
36. Louie, A.Y., Huber, M.M., Ahrens, E.T., Rothbacher, U., Moats, R., Jacobs, R.E., Fraser, S.E., and Meade, T.J., In vivo visualization of gene expression using magnetic resonance imaging, Nat. Biotechnol., 18, 321–325, 2000.
37. Li, W.H., Parigi, G., Fragai, M., Luchinat, C., and Meade, T.J., Mechanistic studies of a calciumdependent MRI contrast agent, Inorg. Chem., 41, 4018–4024, 2002.
38. Lowe, M.P., Activated MR contrast agents, Curr. Pharm. Biotechnol., 5, 519–528, 2004.
39. Aime, S., Delli Castelli, D., and Terreno, E., Novel pH-reporter MRI contrast agents, Angew. Chem. Int. Ed. Engl., 41, 4334–4336, 2002.
40. Aime, S., Botta, M., Fasano, M., Terreno, E., Kinchesh, P., Calabi, L., and Paleari, L., A new ytterbium chelate as contrast agent in chemical shift imaging and temperature sensitive probe for MR spectroscopy, Magn. Reson. Med., 35, 648–651, 1996.
41. Perez, J.M., Josephson, L., O’Loughlin, T., Hogemann, D., and Weissleder, R., Magnetic relaxation switches capable of sensing molecular interactions, Nat. Biotechnol., 20, 816–820, 2002.
42. Cohen, B., Dafni, H., Meir, G., and Neeman, M., Ferritin as novel MR-reporter for molecular imaging of gene expression, Proc. Int. Soc. Magn. Reson. Med., 11, 1707, 2004.
43. Bonnemain, B., Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review, J. Drug Target, 6, 167–174, 1998.
44. Bjornerud, A. and Johansson, L., The utility of superparamagnetic contrast agents in MRI: theoretical consideration and applications in the cardiovascular system, NMR Biomed., 17, 465–477, 2004.
45. Reichert, D.E., Lewis, J.S., and Anderson, C.J., Metal complexes as diagnostic tools, Coordination Chem. Rev., 184, 3–66, 1999.
46. Shapiro, E.M., Sharer, K., Skrtic, S., and Koretsky, A.P., In vivo detection of single cells by MRI, Magn. Reson. Med., 55, 242–249, 2006.
47. Heyn, C., Ronald, J.A., Mackenzie, L.T., MacDonald, I.C., Chambers, A.F., Rutt, B.K., and Foster, P.J., In vivo magnetic resonance imaging of single cells in mouse brain with optical validation, Magn. Reson. Med., 55, 23–29, 2006.
48. Shapiro, E.M., Skrtic, S., Sharer, K., Hill, J.M., Dunbar, C.E., and Koretsky, A.P., MRI detection of single particles for cellular imaging, Proc. Natl. Acad. Sci. U.S.A., 101, 10901–10906, 2004.
49. Ahrens, E.T., Flores, R., Xu, H., and Morel, P.A., In vivo imaging platform for tracking immunotherapeutic cells, Nat. Biotechnol., 23, 983–987, 2005.
50. Schwarz, R., Schuurmans, M., Seelig, J., and Kunnecke, B., 19F-MRI of perfluorononane as a novel contrast modality for gastrointestinal imaging, Magn. Reson. Med., 41, 80–86, 1999.
51. Runge, V.M., Safety of approved MR contrast media for intravenous injection, J. Magn. Reson. Imaging, 12, 205–213, 2000.
52. Li, A., Wong, C.S., Wong, M.K., Lee, C.M., and Au Yeung, M.C., Acute adverse reactions to magnetic resonance contrast media: gadolinium chelates, Br. J. Radiol., 79, 368–371, 2006.
53. Beaudouin, E., Kanny, G., Blanloeil, Y., Guilloux, L., Renaudin, J.M., and Moneret-Vautrin, D.A., Anaphylactic shock induced by gadoterate meglumine (DOTAREM), Allerg. Immunol. (Paris), 35, 382–385, 2003.
54. Chu, W.C., Lam, W.W., and Metreweli, C., Incidence of adverse events after I.V. injection of MR contrast agents in a Chinese population. A comparison between gadopentetate and gadodiamide, Acta Radiol., 41, 662–666, 2000.
55. Marsden, P.K., Strul, D., Keevil, S.F., Williams, S.C., and Cash, D., Simultaneous PET and NMR, Br. J. Radiol., 75, S53–S59, 2002.
56. Jacobs, R.E. and Cherry, S.R., Complementary emerging techniques: high-resolution PET and MRI, Curr. Opin. Neurobiol., 11, 621–629, 2001.
57. Roberts, T.P., Chuang, N., and Roberts, H.C., Neuroimaging: do we really need new contrast agents for MRI? Eur. J. Radiol., 34, 166–178, 2000.